Does LeMaitre’s Earnings Beat, 2025 EPS Guidance and Dividend Payout Change The Bull Case For LMAT?

• LeMaitre Vascular recently reported quarterly earnings that exceeded analyst expectations with earnings per share of $0.62, issued full-year 2025 EPS guidance of $2.48–$2.53, and paid a $0.20 quarterly dividend on December 4, 2025.
• Analyst coverage has coalesced around a “Moderate Buy” view, signaling cautious optimism as the company pairs earnings outperformance with ongoing shareholder returns through regular dividends.
• Next, we’ll consider how LeMaitre’s stronger-than-expected earnings and fresh 2025 EPS guidance interact with its existing investment narrative.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

LeMaitre Vascular Investment Narrative Recap

To own LeMaitre Vascular, you need to believe its niche vascular focus, international expansion, and aging patient base can keep driving steady growth despite a relatively concentrated product portfolio. The latest earnings beat and 2025 EPS guidance support the near term growth catalyst of rising profitability, but they do not remove key risks around pricing sustainability and dependence on a handful of core products.

The recent dividend payment of US$0.20 per share, following earlier increases in 2025, ties directly into the current investment story by reinforcing management’s commitment to ongoing shareholder returns. For investors watching earnings as the main catalyst, this regular cash return adds another layer to assess alongside guidance, especially as they weigh it against margin pressures and future growth expectations.

But while earnings and dividends look encouraging, investors should still pay close attention to how reliant LeMaitre is on a small set of vascular products...

Read the full narrative on LeMaitre Vascular (it's free!)

LeMaitre Vascular's narrative projects $312.8 million revenue and $65.6 million earnings by 2028.

Uncover how LeMaitre Vascular's forecasts yield a $104.78 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community range from around US$60 to above US$5,300 per share, showing how far apart individual views can be. Against that wide spread, the company’s reliance on pricing increases for revenue and margin growth is a key factor readers should explore further when weighing these differing opinions.

Explore 4 other fair value estimates on LeMaitre Vascular - why the stock might be a potential multi-bagger!

Build Your Own LeMaitre Vascular Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your LeMaitre Vascular research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free LeMaitre Vascular research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LeMaitre Vascular's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 34 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com